Advancements in Treating Corneal Injuries and Diseases
A special issue of Journal of Clinical & Translational Ophthalmology (ISSN 2813-1053).
Deadline for manuscript submissions: 15 May 2025 | Viewed by 148
Special Issue Editor
2. Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO, USA
Interests: corneal diseases; corneal injuries; ocular diseases; molecular basis of disease pathogenesis; therapeutic approaches to prevent blindness
Special Issue Information
Dear Colleagues,
The cornea, the outermost and transparent part of the eye, plays a vital role in vision by refracting light and providing a clear path to the retina. Unfortunately, this delicate structure is susceptible to a wide range of injuries (alkali, acid, mechanical, open globe injury, etc.) and diseases (corneal dystrophy, Fuchs’ dystrophy, keratitis, keratoconus, corneal infections, dry eye, corneal scarring, Pterygium), which can lead to vision impairment and blindness if left untreated. In recent years, significant advancements have been made in treating corneal conditions. Treatments include stem cell therapy, gene therapy, drug therapy, artificial cornea development, and many more in the pipeline. Apart from these therapies, artificial corneas, or keratoprostheses, are becoming more refined. Modern designs aim to better integrate with the native eye tissues and improve the long-term success of the implant, including DMEK (Descemet Membrane Endothelial Keratoplasty) and DSAEK (Descemet Stripping Automated Endothelial Keratoplasty), which involves a transplantation of only the innermost layer, endothelium of the cornea, which can lead to a faster recovery and reduced risk of rejection compared to traditional full-thickness corneal transplants. One step ahead of corneal transplantations is the reconstruction of the ocular surface, which can be improved using biomaterials to create scaffolds that support the regeneration of the corneal surface, as well as the development of bioengineered corneal tissues. These tools include artificial intelligence’s (AI) help in tailoring individualized treatment plans and tracking disease progression or response to therapy. Moreover, these advancements collectively improve the management of corneal injuries and diseases, offering better outcomes and quality of life for patients.
This research topic will be a repository for studies that address the aforementioned advancement in corneal injury disease treatments. In addition, we aim to include expert opinions regarding the opportunities and challenges of the field. We welcome original research articles, reviews, case studies, and perspectives that cover the following areas:
- Clinical studies of corneal and ocular surface injuries and diseases.
- Methods/imaging techniques to detect corneal injuries and diseases.
- Identification, characterization, and preclinical scientific validation of corneal therapies and bioactive compounds/stem cell therapy/gene therapy as therapeutic targets.
- Mechanisms that involve insights into stem cell therapy/gene therapy/bioactive compounds as therapeutic targets against ocular diseases using experimental and bioinformatics approaches.
- Strategies to improve corneal injuries and diseases with bioactive compounds, gene therapy, cell therapy, and nanoparticles.
- Understanding the mechanisms of action and combinatorial rules of herbal formulae through network pharmacology.
- Use of AI in treating corneal injuries and diseases.
Dr. Ratnakar Tripathi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical & Translational Ophthalmology is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- corneal injury
- dystrophy
- stem cell
- gene therapy
- drug therapy
- artificial intelligence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
